A safety evaluation of aripiprazole in the treatment of schizophrenia

References

• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93.
   PubMed Web of Science ®Google Scholar
• Dixon LB, Dickerson F, Bellack AS, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):48–70.
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94–103.
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Alexander RC, Egan MF, et al. Schizophrenia, just the facts: what do we know, how well do we know it? Schizophr Res. 1988;1(1):3–18.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MSJ Sr. Schizophrenia,“Just the Facts” 5. Treatment and prevention past, present, and future. Schizophr Res. 2010;122(1–3):1–23.
   PubMed Web of Science ®Google Scholar
• Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015;11:2635.
   PubMed Web of Science ®Google Scholar
• ABILIFY (aripiprazole) tablets, ABILIFY DISCMELT (aripiprazole) orally disintegrating tablets, ABILIFY (aripiprazole) oral solution, ABILIFY (aripiprazole) injection for intramuscular use only; Otsuka Pharmaceutical Company. 2014.
   Google Scholar
• Abilify 7.5 mg/ml solution for injection (intramuscular) - summary of product characteristics (SmPC).
   Google Scholar
• Abilify Package Insert; Otsuka Pharmaceutical Company. 2020.
   Google Scholar
• Abilify maintena package insert; Otsuka Pharmaceutical Company. 2020.
   Google Scholar
• Abilify aristada package insert; Alkermes, Inc. 2019.
   Google Scholar
• ABILIFY MAINTENA; European Medicines Agency.
   Google Scholar
• Application number 207533orig1s000 summary review; center for drug evaluation and research. 2015.
   Google Scholar
• Pae C-U. A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf. 2009;8(3):373–386.
   PubMed Web of Science ®Google Scholar
• Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther. 2010;32:S3–S20.
   PubMed Web of Science ®Google Scholar
• Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol. 2016;9(2):169–186.
   PubMed Web of Science ®Google Scholar
• Rapinesi C, Kotzalidis GD, Mazzarini L, et al. Long-acting injectable (LAI) aripiprazole formulations in the treatment of schizophrenia and bipolar disorder: a systematic review. Clin Drug Investig. 2019;39(8):713-735.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Aripiprazole lauroxil: a review in schizophrenia. Drugs. 2017;77(18):2049–2056.
   PubMed Web of Science ®Google Scholar
• Aristada initio package insert; Alkermes, Inc. 2018.
   Google Scholar
• Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1:” Goldilocks” actions at dopamine receptors. J Clin Psych. 2001;62(11):841–842.
   Google Scholar
• Stahl SM. Brainstorms: dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 2: illustrating Their Mechanism of Action. J Clin Psych. 2001;62(12):923–924.
   Google Scholar
• DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26(5):649–666.
   PubMed Web of Science ®Google Scholar
• Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol. 2003;70(2):83–244.
   PubMed Web of Science ®Google Scholar
• Sparshatt A, Taylor D, Patel MX, et al. A systematic review of aripiprazole–dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psych. 2010;71(11):1447–1456.
   Google Scholar
• Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45(1):89–93.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44(2):179–187.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281–288.
   PubMed Web of Science ®Google Scholar
• Abilify: European Medicines Agency. [Cited 2020 Aug 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/abilify
   Google Scholar
• Lieberman J, Carson W, Saha A, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia. Int J Neuropsychopharmacol. 2002;5(Suppl 1):S186.
   Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6(4):325–337.
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psych. 2003;64(9):1048-56.
   Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011 Apr;127(1–3):93–99.
   PubMed Web of Science ®Google Scholar
• Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008 May;69(5):720–731.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010 Sep;13(8):1115–1125.
   PubMed Web of Science ®Google Scholar
• Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psych. 2014;75(11):1254–1260.
   Google Scholar
• Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psych. 2012;73(5):617–624.
   Google Scholar
• Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014 Aug;205(2):135–144.
   PubMed Web of Science ®Google Scholar
• Ishigooka J, Nakamura J, Fujii Y, et al. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015 Feb;161(2–3):421–428.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psych. 2015;76(8):1085–1090.
   Google Scholar
• Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–1943.
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2–3):123–136.
   PubMed Web of Science ®Google Scholar
• Christensen AP, Boegevig S, Christensen MB, et al. Overdoses with aripiprazole: signs, symptoms and outcome in 239 exposures reported to the Danish poison information centre. Basic Clin Pharmacol Toxicol. 2018;122(2):293–298.
   PubMed Web of Science ®Google Scholar
• Food U, Administration D. FDA drug safety communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada) 2016. [cited 2020 Aug 3 Aug 16]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-new-impulse-control-problems-associated-mental-health
   Google Scholar
• Etminan M, Sodhi M, Samii A, et al. Risk of gambling disorder and impulse control disorder with aripiprazole, pramipexole, and ropinirole: a pharmacoepidemiologic study. J Clin Psychopharmacol. 2017;37(1):102–104.
   PubMed Web of Science ®Google Scholar
• Lertxundi U, Hernandez R, Medrano J, et al. Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation? Int Clin Psychopharmacol. 2018;33(1):56–58.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Khanna P, Suo T, Komossa K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014 Jan;2(1):CD006569.
   Google Scholar
• Aripiprazole prolonged release suspension for injection (abilify maintena) (300 mg and 400 mg vial). CADTH Common Drug Reviews. Ottawa (ON). 2017.
   Google Scholar
• Luedecke D, Schöttle D, Karow A, et al. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. CNS Drugs. 2015;29(1):41–46.
   Google Scholar
• Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015 Oct;168(1–2):498–504.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Aquila R, Du Y, et al. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectr. 2019 Aug;24(4):395–403.
   PubMed Web of Science ®Google Scholar
• Kim J, Ozzoude M, Nakajima S, et al. Insight and medication adherence in schizophrenia: an analysis of the CATIE trial. Neuropharmacology. 2020;168:107634.
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018 Feb;21(2):127–134.
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24.
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013 Jun;74(6):568–575.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014 Feb;19(1):3–5.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011 Jun;168(6):603–609.
   PubMed Web of Science ®Google Scholar